<DOC>
	<DOCNO>NCT01560637</DOCNO>
	<brief_summary>This study international , multi-center , open-label study design provide oral treprostinil ( UT-15C ) eligible subject pulmonary arterial hypertension complete TDE-PH-310 study . The purpose study ass long-term safety UT-15C ass effect long-term treatment UT-15C exercise capacity .</brief_summary>
	<brief_title>An Open-Label , Long-Term Study Oral Treprostinil Subjects With Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>Participated United Therapeutics Study TDEPH310 Premature discontinuation United Therapeutics Study TDEPH310 due reason clinical worsening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>PAH</keyword>
	<keyword>PH</keyword>
	<keyword>FREEDOM</keyword>
	<keyword>6 minute walk test</keyword>
	<keyword>treprostinil</keyword>
	<keyword>open label</keyword>
</DOC>